grant
Targeting inflammation to improve rescue of CFTR by modulator therapy
Organization UNIVERSITY OF KANSAS MEDICAL CENTERLocation KANSAS CITY, UNITED STATESPosted 18 May 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2025AffectAngiotensin II ReceptorAnti-Hypertensive AgentsAnti-Hypertensive DrugsAnti-HypertensivesAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryBiometricsBiometryBiostatisticsBlindedBone-Derived Transforming Growth FactorCF lung diseaseCF patientsCFTRCFTR ProteinCOX-2 proteinCOX2 enzymeCell Communication and SignalingCell SignalingChildhoodChloridesChronicClinicClinicalClinical ResearchClinical StudyClinical TrialsClinical Trials DesignCross Sectional AnalysisCross-Sectional AnalysesCross-Sectional StudiesCross-Sectional SurveyCyclo-Oxygenase-2Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDNA mutationDataDefectDelta F508 mutationDevelopment PlansDiagnosticDisease Frequency SurveysDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrugsEnrollmentEnsureEpithelial CellsEvaluationF508 deletionF508 mutationF508-delF508delFDA approvedGenesGenetic ChangeGenetic DiseasesGenetic defectGenetic mutationGoalsHumanHydrationHydration statusHyperglycemiaHypotensive AgentHypotensive DrugsIbuprofenImpairmentIn VitroIndividualInflammationInflammation MediatorsIntracellular Communication and SignalingInvestigatorsIon ChannelIonic ChannelsIvacaftorK23 AwardK23 MechanismK23 ProgramKnowledgeLeadLengthLifeLinkLiquid substanceLosartanLung infectionsMeasurementMeasuresMediatorMedicationMembrane ChannelsMentored Patient-Oriented Research Career Development AwardMentored Patient-Oriented Research Career Development Award (K23)MentorsMethodsMilk Growth FactorModern ManMorbidityMorbidity - disease rateMotrinMucociliary ClearanceMucociliary TransportMucous body substanceMucoviscidosisMucusMutationNasalNasal EpitheliumNasal Passages NoseNoseObservation researchObservation studyObservational StudyObservational researchOutcomePGH Synthase 2PGHS2PHS IIPatientsPb elementPersonsPharmaceutical PreparationsPilot ProjectsPlatelet Transforming Growth FactorPopulationPositionPositioning AttributePropertyProstaglandin G/H Synthase 2Prostaglandin H2 Synthase 2Prostaglandin-Endoperoxide Synthase 2ProteinsPulmonary Cystic FibrosisQOLQuality of lifeRandomizedRegression AnalysesRegression AnalysisRegression DiagnosticsResearchResearch PersonnelResearchersRespiratory System, Nose, Nasal PassagesSamplingSignal TransductionSignal Transduction SystemsSignalingStatistical RegressionSurrogate MarkersTGF BTGF-Beta 1TGF-Beta1TGF-betaTGF-βTGFBTGFB1TGFB1 geneTGFbetaTGFβTechniquesTestingTherapy trialTimeTrainingTransforming Growth Factor Beta 1Transforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslatingUnited StatesVX-770airway epithelium inflammationairway inflammationairway surface liquidanti-hypertensionbiological signal transductionbronchial epitheliumcareer developmentcustomized therapycustomized treatmentcyclo-oxygenase IIcyclooxygenase 2cystic fibrosis lungcystic fibrosis lung diseasecystic fibrosis patientscystic fibrosis transmembrane regulatorcytokinedesigndesigningdrug/agentenrollexperiencefluidfunctional restorationgenetic conditiongenetic disordergenome mutationheavy metal Pbheavy metal leadhyperglycemicimprovedimproved outcomein vivoindividualized medicineindividualized patient treatmentindividualized therapeutic strategyindividualized therapyindividualized treatmentindividuals with CFindividuals with cystic fibrosisinflammation markerinflammatory markerinflammatory mediatorinhibitorinsightliquidlozartanlung functionlung function declinemRNA Expressionmicrobial colonizationmortalitymucousmutantnext generationnovelpatient screeningpatient specific therapiespatient specific treatmentpatients with CFpatients with cystic fibrosispediatricperipheral bloodpilot studypre-clinicalpreclinicalprognosticprostaglandin H synthase-2pulmonarypulmonary functionpulmonary function declinepulmonary infectionsrandomisationrandomizationrandomly assignedrespiratory inflammationrespiratory tract inflammationresponseresponse to therapyresponse to treatmentrestore functionrestore functionalityrestore lost functionsecondary outcomesurrogate bio-markerssurrogate biomarkerstailored medical treatmenttailored therapytailored treatmenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy responsetransforming growth factor beta1treatment responsetreatment responsivenessunique treatmentΔF508
Description preview
PROJECT SUMMARY
Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding CF transmembrane
conductance regulator (CFTR), an ion channel essential for mucus hydration. Improper hydration of mucus leads
to airway inflammation, chronic pulmonary infections and abnormal mucociliary function. The major contributor
to morbidity…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click